Citigroup - Mylan "buy"

Datum Erster Hoch Tief Schluss     Stücke Volumen
05.09.13 35,95 36,07 35,65  35,875 $ 1.687.800 59,7 M

GrB  

to Speak at the Morgan Stanley Global Healthcare Unplugged Conference15:50 05.09.13


PR Newswire

PITTSBURGH, Sept. 5, 2013

PITTSBURGH, Sept. 5, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that Chief Financial Officer John Sheehan will speak at the Morgan Stanley Global Healthcare Unplugged Conference on Tuesday Sept. 10, 2013 at 3:30 p.m. EDT,  at the Grand Hyatt New York. The conference will be webcast live and can be accessed on Mylan's Investor Relations Web site at http://investor.mylan.com/.

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same location for a limited time.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.


Quelle: PR Newswire  

http://www.ariva.de/news/...ynch-Global-Healthcare-Conference-4767007 GrB

..SK 35,875 $ SKP +0,00 Pott+392,79%  

und Stuttgart

Zeit  Kurs  Stück  
11:48:11 26,93 €  100  
08:05:03 26,55 €  0

beiden Teilnehmern herzlichen Glückwunsch und Dreimal Rosamunde ..buran  

http://www.ariva.de/news/...unities-to-Talk-About-Anaphylaxis-4769231 GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
06.09.13 35,89 35,99 34,86  35,29 $ 5.294.385 132 M

GrB  

und nächste Abfahrt mit 35,22 $ Warte 2.700 spread 0,03% / alles RT / buran

.........and GO  

Datum Erster Hoch Tief Schluss     Stücke Volumen
20.09.13 38,42 39,03 38,42  38,66 $ 5.108.247 189 M

GrB  

Price: 38.66
Change: + 0.33
Day High: 39.03
Day Low: 38.42
Volume: 5,003,000
http://investor.mylan.com/  

Date Open High Low Close Volume
Sep 16, 2013 39.35 39.41 38.77 38.95 4,652,637
Sep 17, 2013 39.36 39.36 38.50 38.50 3,791,521
Sep 18, 2013 38.44 38.82 38.06 38.60 6,085,756
Sep 19, 2013 38.59 38.91 38.26 38.33 4,004,586
Sep 20, 2013 38.42 39.03 38.42 38.66 5,430,808
http://investor.mylan.com/stocklookup.cfm  

to Uphold Consistent, Proven International Standard for Biosimilar Naming07:30 23.09.13


PR Newswire

PITTSBURGH, Sept. 23, 2013

PITTSBURGH, Sept. 23, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today expressed support for the Generic Pharmaceutical Association's (GPhA) filing of an official Citizen Petition with the Food and Drug Administration (FDA) detailing the industry's position on biosimilar naming. The petition recommends that all biosimilars approved by the agency share the same international non-proprietary name (INN) as the biologic products to which they refer. A drug's INN serves to clearly and universally state a medicine's main substance or ingredient – for example, Lipitor®'s INN, or generic name, is Atorvastatin Calcium. An approved biosimilar product will have been shown through rigorous physicochemical and functional testing to be as close to the reference product as the reference product is to itself from lot to lot, but with more affordability. It is therefore critical for the medical community to continue identifying biosimilars using the same naming convention as other medicines available to patients today.

Mylan CEO Heather Bresch commented: "Mylan's mission to set new standards in health care and expand access to high quality medicine is aligned with GPhA's Citizen Petition to FDA regarding the use of consistent international standards for biosimilar naming. The use of consistent INN's ensures patient safety as it helps to protect patients from concerns such as double dosing where two highly similar products may be prescribed."

The importance of consistent INN's to patient safety can be illustrated by the more than 150 different biologic INN's with over 250 different trade names on the market today. If each biologic were to have just four biosimilar options (i.e. fewer competitors than the average path taken by small molecules which have an average of 12 manufacturers per product), 600 new INN's would be added to the biologic products presently available. The unnecessary increase in unique product names could serve to confuse health care providers, put patient outcomes at risk and only further delay access to these critical products.

Bresch continued: "The use of a consistent INN naming standard has been in place for more than 50 years and is used in scores of countries around the world. Multiple biologics have already been approved in the U.S. using the same INN, and continuing to use this proven naming methodology represents an important step to ensure that patients in the U.S. and elsewhere can benefit from expanded access to more affordable biologic medicines."

Mylan urges the wide variety of impacted stakeholders to continue working together to maintain and expand access to high quality medicines in the U.S., including biosimilar drugs that share the same INN name as their reference product.

For more information about GPhA's Citizen Petition, please access the full letter. For more information about biosimilars, visit: http://www.gphaonline.org/issues/biosimilars.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.


Quelle: PR Newswire  

::::::::: 38,275 $ +0,38% +0,1453 $ In Euro: 28,298 € | Nasdaq ,GrB  

RTK 38,275 $ RTP +0,38 EK 38,13 $ last 100 full 1.871.496 peak 38,30 ,GrB  

Mylan Confirms First-to-File Patent Challenge Relating to SAVELLA®08:38 25.09.13


PR Newswire

PITTSBURGH, Sept. 25, 2013

PITTSBURGH, Sept. 25, 2013 /PRNewswire/ --  today confirmed that the company has been sued by Forest Laboratories Inc., Forest Laboratories Holdings Ltd., and Royalty Pharma Collection Trust in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Milnacipran HCl Tablets 12.5 mg, 25 mg, 50 mg and 100 mg. This product is the generic version of SAVELLA®, which is indicated for the management of fibromyalgia. This product is not approved for use in pediatric patients.(1)

Mylan believes it is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and expects to be eligible for 180 days of marketing exclusivity upon final FDA approval. The plaintiffs have filed a lawsuit against Mylan in the United States District Court for the District of Delaware.

For the 12 months ending June 30, 2013, SAVELLA had U.S. sales of approximately $123 million, according to IMS Health.

Currently, Mylan has 178 ANDAs pending FDA approval representing $83.8 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $23.8 billion in annual brand sales, for the 12 months ending Dec. 31, 2012, according to IMS Health.

This press release includes statements that constitute "forward-looking statements," including with regard to the expected first-to-file status and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

(1)  Milnacipran HCl, like other selective serotonin and norepinephrine reuptake inhibitors (SNRI), have been shown to increase the risk of suicidal ideation, thinking, and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder (MDD) and other psychiatric disorders when compared to placebo.

SOURCE Mylan Inc.


Quelle: PR Newswire  

::::::::::: 39,99 $ +1,27% +0,50 $ In Euro: 29,362 € | Nasdaq, 22:00 ,GrB  

Financial Results Conference Call and Live Webcast11:54 07.10.13


PR Newswire

PITTSBURGH, Oct. 7, 2013

PITTSBURGH, Oct. 7, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast Thursday, Oct. 31, 2013, at 10:00 a.m. ET, to review the company's financial results for the third quarter, which ended Sept 30, 2013. Mylan will release its financial results on Oct. 31 before the market opens.

The dial-in number to access the call is 877.402.3913, or 817.382.5964 for international callers. A replay will be available two hours after the calls completion for approximately seven days at 800.585.8367, or 404.537.3406 for international callers, with access pass code 77498768.

To access a live webcast of the call, please log on to Mylan's website (www.mylan.com) at least 15 minutes before the event is scheduled to begin to register and download or install any necessary software. A replay of the webcast will be available on www.mylan.com for approximately seven days.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.


Quelle: PR Newswire  

des europäischen Geschäftszweigs von Mylan03:29 18.10.13

Pittsburgh (ots/PRNewswire) - Mylan Inc. gab heute die Ernennung von Jacek Glinka zum Präsidenten des europäischen Geschäftszweigs von Mylan bekannt. Die Ernennung wird zum 2. Dez. 2013 wirksam. Glinka wird an Hal Korman, dem COO von Mylan, berichten.

Bevor Glinka zu Milan hinzukam, war er von 2003 bis 2006 und von 2009 bis 2013 als CEO der Polpharma Group tätig. Während seiner Anstellung leitete er die Umwandlung von Polpharma von einem kleinen lokalen Akteur hin zu einem führenden Pharmaunternehmen in Zentral- und Osteuropa, im Kaukasus und in Zentralasien. Unter seiner Führung wurde Polpharma zu einem führenden Unternehmen auf dem polnischen Markt und zu einem der am schnellsten wachsenden Pharmaunternehmen in der Region. Im Zeitraum von 2011 bis 2013 verdoppelte Polpharma seinen Umsatz auf mehr als 1 Milliarde $. Unter Glinkas Führung führte Polpharma zudem die erfolgreiche Übernahme und Integration einer Reihe von Unternehmen wie Chimpharm in Kasachstan, Polfa Warsaw in Polen, die Abteilung für Antibiotika von Bioton in Polen und das Nutrazeutikaportfolio von Herbapol durch. Darüber hinaus leitete Glinka die strategische Expansion in neue Länder - sowohl durch organisches Wachstum als auch durch Akquisition. Zu diesen neuen Ländern gehören Kasachstan, Usbekistan, Aserbaidschan und Vietnam. Darüber hinaus verbesserte er auch die organisatorische Struktur und die Prozesse im Unternehmen und implementierte mehrere unternehmensweite Kostensenkungsprogramme, die zu substanziellen Verbesserungen in der Rentabilität von Polpharma führten.

Heather Bresch, CEO von Mylan, kommentierte: "Wir sind begeistert, Jacek bei Mylan willkommen heißen zu können. Seine außergewöhnliche Erfolgsgeschichte bei der Führung von Polpharma spricht für sich selbst und wir sind der festen Überzeugung, dass seine umfangreichen Erfahrungen in dieser Region zum kontinuierlichen Erfolg und zum Wachstum von Mylan in Europa beitragen werden. Wir sind der Meinung, dass Jaceks starke Führungskraft, sein strategisches Denken und seine betriebliche Disziplin auf unseren bereits vorhandenen, soliden Basis- und Führungsteams aufbauen werden, womit die vielen Möglichkeit maximal genutzt werden, welche wir für unseren europäischen Geschäftszweig vorhersehen."

Glinka erklärte: "Ich habe die Aktivitäten von Mylan seit einer Weile eingehend verfolgt, und ich bin der Meinung, dass die massive weltweite, vertikale Integration, das breit angelegte Produktportfolio sowie der unbeirrte Einsatz für Qualität zu den wahren Unterscheidungsmerkmalen auf diesem heiß umkämpften und diversifizierten europäischen Markt gehören. Ich freue mich darauf, mit den weltweit und regional verantwortlichen Führungskräften von Mylan zusammenzuarbeiten, um die Stärke des Programms von Mylan regionsübergreifend zu maximieren sowie die führende Position von Mylan in den Schlüsselmärkten weiter zu stärken. Darüber hinaus freue ich mich auch, meine Expertise zu nutzen, im Besonderen auf den aufregenden Märkten in Zentral- und Osteuropa, um den Wirkungsbereich von Mylan weiter auszuweiten.

Bevor Glinka Polpharma leitete, war er als Geschäftsführer von Spectra Services tätig, wo er eine Reihe von Akquisitionen und Umstrukturierungen verwaltete, unter anderem die Akquisition und die Integration von Akrihin in die Polpharma Group. Er begann seine professionelle Karriere als strategischer Managementberater bei Unternehmen wie Deloitte & Touche und A.T. Kearney.

Glinka war ein Mitglied der Aufsichtsräte von Medana Pharma, OAO Akrihin (Präsident des Aufsichtsrats), Chimpharm, Polfa Lublin (Präsident des Aufsichtsrats), Herbapol Lublin (Vizepräsident des Aufsichtsrats), ZT Kruszwica und Spectra Investments tätig. Er erhielt seinen Abschluss von der Warsaw Business School.

Diese Pressemitteilung enthält Aussagen, die "zukunftsweisende Aussagen" darstellen. Diese beziehen sich unter anderem auf das zukünftige Wachstum und die Leistung des Unternehmens. Diese Aussagen werden gemäß den "Safe Harbour"-Bestimmungen des Private Securities Litigation Reform Act aus dem Jahr 1995 getroffen. Da solche Aussagen naturgemäß Risiken und Unsicherheiten enthalten, können sich die zukünftigen Ergebnisse materiell von denen unterscheiden, die implizit oder explizit in den zukunftsweisenden Aussagen enthalten sind. Zu den Faktoren, die zu solchen Abweichungen beitragen oder welche diese verursachen können, gehören unter anderem: der Einfluss von Wettbewerb; Änderungen der wirtschaftlichen und finanziellen Bedingungen des Geschäfts des Unternehmens; die Fähigkeit des Unternehmens, Schlüsselpersonal anzuziehen und zu halten; Unsicherheiten und Angelegenheiten außerhalb der Kontrolle des Managements; sowie andere Risiken, welche in den Einreichungen des Unternehmens bei der Securities and Exchange Commission enthalten sind. Das Unternehmen übernimmt keine Verpflichtung, diese Aussagen aufgrund von Revisionen beziehungsweise Änderungen nach dem Veröffentlichungsdatum dieser Pressemitteilung zu aktualisieren.

Mylan ist ein weltweit tätiges Pharmaunternehmen, welches es sich zur Aufgabe gesetzt hat, neue Standards im Gesundheitswesen zu schaffen. Wir arbeiten auf weltweiter Ebene zusammen, um 7 Milliarden Menschen Zugang zu hochwertigen Arzneimitteln zu ermöglichen. Wir schaffen Innovationen um unerfüllte Bedürfnisse zu erfüllen, machen Zuverlässigkeit und exzellenten Service zum Standard, fällen richtige - anstatt einfache Entscheidungen und beeinflussen durch unsere ambitionierte Führungsrolle weltweit die Zukunft. Wir bieten ein wachsendes Portfolio von ca. 1.100 generischen Arzneimitteln und verschiedene Markenpräparate an. Zusätzlich bieten wir eine große Auswahl an antiretroviralen Therapien an, auf die ca. 40 % aller HIV/AIDS-Patienten in Entwicklungsländern angewiesen sind. Wir sind ebenfalls einer der weltweit größten Hersteller von Arzneimittelwirkstoffen (API). Aktuell bieten wir unsere Produkte in ca. 140 Ländern und Regionen an. Mehr als 20.000 Beschäftigte weltweit widmen sich der Verbesserung der Kundenzufriedenheit und fördern den Zugang zu Arzneimitteln für Patienten überall auf der Welt. Aber nehmen Sie uns nicht nur beim Wort, sondern sehen Sie selbst: Machen Sie sich ein Bild: mylan.com

Web site: http://www.mylan.com/

OTS: Mylan Laboratories Inc. newsroom: http://www.presseportal.de/pm/63315 newsroom via RSS: http://www.presseportal.de/rss/pm_63315.rss2

Pressekontakt: KONTAKT: Nina Devlin (Medien), +1-724-514-1968, Kris King (Investoren), +1-724-514-1813

Quelle: OTS  

Relating to Uloric®

16:10 01.11.13

PR Newswire

PITTSBURGH, Nov. 1, 2013

PITTSBURGH, Nov. 1, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has been sued by Teijin Limited, Teijin Pharma Limited and Takeda Pharmaceuticals U.S.A., Inc., in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Febuxostat Tablets, 40 mg and 80 mg. This product is the generic version of Uloric®, which is indicated for the chronic management of hyperuricemia in patients with gout. It is not recommended for the treatment of asymptomatic hyperuricemia.

Mylan believes it is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and expects to be eligible for 180 days of marketing exclusivity upon final FDA approval. The plaintiffs have filed a lawsuit against Mylan in the United States District Court for the District of Delaware.

For the 12 months ending June 30, 2013, Uloric had U.S. sales of approximately $260.7 million, according to IMS Health.

Currently, Mylan has 179 ANDAs pending FDA approval representing $84.6 billion in annual sales, according to IMS Health. Forty of these pending ANDAs are potential first-to-file opportunities, representing $24.1 billion in annual brand sales, for the 12 months ending June 30, 2013, according to IMS Health.

This press release includes statements that constitute "forward-looking statements," including with regard to the expected first-to-file status and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.
Quelle: PR Newswire  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  11.11.13     40,41     41,17§40,03 41,06 $ 5.046.570 205 M

GrB  

Credit Suisse Healthcare Conference

22:35 06.11.13

PR Newswire

PITTSBURGH, Nov. 6, 2013

PITTSBURGH, Nov. 6, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the 2013 Credit Suisse Healthcare Conference on Wednesday, Nov. 13, 2013 at 4:00 p.m. ET at The Phoenician Resort, Scottsdale, AZ. The conference will be webcast live and can be accessed on Mylan's Investor Relations Web site at http://investor.mylan.com/.

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same location for a limited time.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.
Quelle: PR Newswire  

RTK 30,11 € RTP -0,13 Pott +312,47% ,GrB  

Mylan Launches Generic Version of Aciphex® Tablets

13:35 11.11.13

PR Newswire

PITTSBURGH, Nov. 11, 2013

PITTSBURGH, Nov. 11, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Rabeprazole Sodium Delayed-release Tablets, 20 mg. Rabeprazole Sodium Delayed-release Tablets are the generic version of Eisai Corporation's Aciphex® Tablets, and are indicated for short-term treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease, and for short-term treatment in the healing and symptomatic relief of duodenal ulcers. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.

Aciphex Tablets, 20 mg, had U.S. sales of approximately $830.1 million for the 12 months ending Sept. 30, 2013, according to IMS Health.

Currently, Mylan has 179 ANDAs pending FDA approval representing $90.5 billion in annual sales, according to IMS Health. Forty of these pending ANDAs are potential first-to-file opportunities, representing $24.1 billion in annual brand sales, for the 12 months ending June 30, 2013, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.
Quelle: PR Newswire  

Zeit   Kurs Stück
  10:44:32§30,935 € 20
__________________
GRATULATION  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  13.11.13     40,46    41,695§40,36 41,62 $ 4.756.829 190 M

GrB  

http://www.ariva.de/news/...aphylaxis-Preparedness-in-Schools-4845939 GrB